Xultophy 100/3.6: payments to doctors
Payments that named Xultophy 100/3.6 as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.4M
- Providers
- 11,268
- Transactions
- 32,829
- Average per transaction
- $43
The per-transaction average — $43 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,268 providers the average total is $125, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novo Nordisk | $1,383,782 | 98.0% |
| Novo Nordisk AS | $25,626 | 1.8% |
| Novo Nordisk Health Care AG | $2,000 | 0.1% |